Amgen's portfolio strength and the MariTide obesity opportunity
Amgen's existing business generates approximately $33 billion in annual revenue from a portfolio of mature biologics that, while facing biosimilar competition in some segments, retain significant pricing power with payers and strong brand loyalty among prescribers. Prolia and Xgeva in bone disease, Repatha in cardiovascular prevention, and Otezla in inflammatory diseases collectively produce billions in stable, recurring revenue that funds R&D investment and substantial share buybacks. This cash flow durability distinguishes Amgen from pure clinical-stage biotechs where all value is option-based — AMGN has real earnings regardless of what happens with pipeline candidates.
MariTide is the pipeline asset that has re-ignited investor interest in Amgen as a growth story rather than a mature biotech. Unlike the established GLP-1 drugs (Ozempic, Wegovy, Mounjaro) that mimic the GLP-1 hormone to suppress appetite and slow gastric emptying, MariTide targets both GLP-1 receptor agonism and GIPR antagonism — a dual mechanism that clinical data suggests may provide better body composition results (more fat mass lost, less lean muscle mass lost) than single-mechanism GLP-1 drugs. If that mechanistic advantage translates to Phase 3 outcomes, it could position MariTide as a premium-priced obesity drug that captures patients who want to preserve muscle during weight loss.
The obesity drug market is projected to exceed $100 billion in annual global sales by 2030, and Amgen entering this space even as a late-stage entrant could represent a company-defining product cycle. Each Phase 2 and Phase 3 data readout from MariTide studies becomes a potential stock-moving catalyst, and the comparison against Novo Nordisk's Wegovy results (the benchmark head-to-head comparison investors will scrutinize) determines whether MariTide will be valued as a genuine competitor or a niche entrant.
- MariTide Phase 2 and Phase 3 weight loss data — percent body weight reduction and lean mass preservation vs. placebo — are the most important clinical data points to monitor for bull/bear case assessment.
- Amgen's quarterly earnings biosimilar competition disclosures track how fast generic biologics are eroding revenue from Enbrel and Prolia in key markets — moderate erosion is expected; faster erosion is a downside surprise.
- Free cash flow per share is Amgen's most important fundamental metric — it funds the $8+ billion annual buyback program that provides per-share earnings growth even when revenue growth is modest.